Compare Cloudflare Inc (NET) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cloudflare Inc vs Travere Therapeutics Inc. Common Stock — how do they compare? Cloudflare Inc trades at $318.2 (market cap $123.81B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Cloudflare Inc is far larger — about 25.4× Travere Therapeutics Inc. Common Stock's market cap, and Cloudflare Inc is trading nearer its 52-week high, Travere Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cloudflare Inc for 61 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| NET | TVTX | |
|---|---|---|
Market Cap | $123.81B | $4.88B |
Volume | 1,745,042 | 1,668,577 |
Sector | Technology | Health |
52-Week High | $361.00 | $67.52 |
52-Week Low | $160.16 | $26.79 |
Typical Hold Time | 61 Days | 0 Days |
Enterprise Value | $123.18B | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cloudflare (NET) trades at $324.01, down 7.6% over 24 hours, amid a mixed technical and fundamental backdrop. The stock shows a bullish moving average signal but neutral oscillators, with key support at $328. Fundamentally, revenue growth is strong, reaching $2.17B in 2025, but profitability remains a challenge with a net income margin of -8.21%. Recent news highlights product launches like Cloudflare Basin and a partnership with Deutsche Telekom, driving positive sentiment.
The outlook is cautiously optimistic, supported by analyst consensus and strategic initiatives, but high valuation multiples and persistent losses pose risks. Investment opportunity lies in continued top-line expansion and market share gains, while key risks include competitive pressures and execution on path to profitability.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cloudflare Inc
Cloudflare is a software company based in San Francisco, California, that offers security and web performance offerings by utilizing a distributed, serverless content delivery network, or CDN. The firm's edge computing platform, Workers, leverages this network by providing clients the ability to deploy, and execute code without maintaining servers.
Read more on NET →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
